Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 9/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174072 | 0.87 | TGM2 (0.53) | BTKITKTEKEPHB4KDR | |
| SCHEMBL1812917 | 0.80 | XIAP (0.56) | XIAPBIRC2ALDH1A1KDM4EMAPT | |
| SCHEMBL31357334 | 0.79 | CHRNB2 (0.52) | BTKITKTEKEPHB4KDR | |
| SCHEMBL9952792 | 0.79 | CHRNB2 (0.52) | BTKITKTEKEPHB4KDR | |
| SCHEMBL16765858 | 0.79 | XIAP (0.41) | XIAPBIRC2BTKTGM2ALDH1A1 | |
| SCHEMBL18891093 | 0.79 | XIAP (0.48) | XIAPBIRC2BTKITKTEK | |
| SCHEMBL13403439 | 0.78 | XIAP (0.62) | XIAPBIRC2ALDH1A1KDM4EMAPT | |
| SCHEMBL4377108 | 0.78 | XIAP (0.62) | XIAPBIRC2ALDH1A1KDM4EMAPT | |
| SCHEMBL28443489 | 0.78 | KDM4E (0.63) | BTKITKTEKEPHB4KDR | |
| SCHEMBL30469520 | 0.78 | KDM4E (0.63) | BTKITKTEKEPHB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| EP-2445479-B1 | ORAL CARE COMPOSITIONS COMPRISING A POLYMERIC DYE | UNILEVER PLC (GB) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
| US-9138600-B2 | Oral care compositions comprising a polymeric dye | CONOPCO, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2443220-B1 | DETERGENT COMPOSITION COMPRISING ANIONIC DYE POLYMER | UNILEVER PLC (GB) | 2013-08-21 | — | — | EP | disclosed |
| EP-2547321-A2 | METHOD OF TREATING HAIR | Unilever PLC (GB) | 2013-01-23 | — | — | EP | disclosed |
| EP-2547319-A2 | METHOD OF TREATING HAIR | Unilever PLC (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113250-A1 | METHOD OF TREATING HAIR | UNILEVER PLC (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113249-A1 | METHOD OF TREATING HAIR | UNILEVER PLC (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113676-A2 | METHOD OF TREATING HAIR | UNILEVER PLC (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113675-A2 | METHOD OF TREATING HAIR | UNILEVER PLC (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010149534-A2 | ORAL CARE COMPOSITIONS | UNILEVER PLC (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010145887-A1 | ANIONIC DYE POLYMERS | UNILEVER PLC (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010142503-A1 | CATIONIC DYE POLYMERS | UNILEVER PLC (GB) | 2010-12-16 | — | — | WO | disclosed |
| US-7332553-B2 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070106041-A1 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB (SE) | 2007-05-10 | — | — | US | disclosed |
| US-7208557-B2 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB (SE) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | XIAP 2996/4885BIRC2 4174/4885BTK 25/4885 |
| US-20070106041-A1 | Functional monomers for molecular recognition and catalysis | PCNA, MUS81, PNMT | XIAP 1390/4885BIRC2 905/4885BTK 3953/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | XIAP 2996/4885BIRC2 4174/4885BTK 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.